-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, W0ZXGGj4EzhuWEsDHBIEC5XKkNcq3oq/rbp13lE7K+f+ktdbMy0ypyG0SuP7Z52X 5vpyk3CZAXwUdrkenmKLoA== 0001356018-07-000478.txt : 20071114 0001356018-07-000478.hdr.sgml : 20071114 20071114103746 ACCESSION NUMBER: 0001356018-07-000478 CONFORMED SUBMISSION TYPE: NT 10-Q PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20070930 FILED AS OF DATE: 20071114 DATE AS OF CHANGE: 20071114 EFFECTIVENESS DATE: 20071114 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Worldwide Biotech & Pharmaceutical CO CENTRAL INDEX KEY: 0000095302 STANDARD INDUSTRIAL CLASSIFICATION: WHOLESALE-GROCERIES & RELATED PRODUCTS [5140] IRS NUMBER: 590950777 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: NT 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-06914 FILM NUMBER: 071241417 BUSINESS ADDRESS: STREET 1: 110 SARASOTA QUAY CITY: SARASOTA STATE: FL ZIP: 34236 BUSINESS PHONE: 941-365-2521 MAIL ADDRESS: STREET 1: 110 SARASOTA QUAY CITY: SARASOTA STATE: FL ZIP: 34236 FORMER COMPANY: FORMER CONFORMED NAME: SUN CITY INDUSTRIES INC DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: SUN CITY DAIRY PRODUCTS INC DATE OF NAME CHANGE: 19690727 NT 10-Q 1 ntq.htm WORLDWIDE BIOTECH NT-10Q 093007 ntq.htm
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


FORM 12b-25
 
NOTIFICATION OF LATE FILING


(Check One)
Form 10-K
o
Form 11-K
o
Form 20-F
o
Form 10-Q
x
Form N-SAR
o

For Period Ended: September 30, 2007

o Transition Report on Form 10-K
o Transition Report on Form 20-F
o Transition Report on Form 11-K
o Transition Report on Form 10-Q
o Transition Report on Form N-SAR

For the Transitional Period Ended: ___________

Read Instruction (on back page) Before Preparing Form. Please Print or Type. Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:


PART I - REGISTRANT INFORMATION


WORLDWIDE BIOTECH & PHARMACEUTICAL COMPANY
Full Name of Registrant


4 Fenghui South Rd., Jie Zuo Mansion, A10 - 11501
Address of Principal Executive Office (Street and Number)


Xi'an, Shaanxi, P.R. China 710075
City, State and Zip Code


 
- 1 -
 


PART II - RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

o
(a)
The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
     
x
(b)
The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K or Form N-SAR, or portion thereof will be filed on or before the 15th calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q, or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and
     
o
(c)
The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.


PART III - NARRATIVE

State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, N-SAR, or the transition report or portion thereof, could not be filed within the prescribed time period.

The Registrant is in the process of preparing and reviewing the financial information of the Company. The process of compiling and disseminating the information required to be included in the Form 10-QSB for the relevant fiscal quarter, as well as the completion of the required review of the Company's financial information, could not be completed without incurring undue hardship and expense. The Registrant undertakes the responsibility to file such quarterly report no later than five days after its original date.


PART IV - OTHER INFORMATION

1)  
Name and telephone number of person to contact in regard to this notification.

Yu Hui Liu
 
(011 - 8629)
 
88193339
(Name)
 
(Area Code)
 
(Telephone Number)

2)  
Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). x Yeso No

3)  
Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? o Yes    x No

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

 

 
- 2 -
 

 
 
SIGNATURES
 

 

WORLDWIDE BIOTECH & PHARMACEUTICAL COMPANY
(Name of Registrant as Specified in Charter)


has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.


Date: November 14, 2007
 
By: /s/ Wenxia Guo
 
 
Wenxia Guo
 
 
Chief Executive Officer

 
 

 

 
- 3 -
 

 -----END PRIVACY-ENHANCED MESSAGE-----